CHINA SXT PHARMACEUTICALS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.025 USD | -3.30% |
|
-4.21% | -74.18% |
| 04-05 | China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended September 30, 2023 | CI |
| 02-08 | Wall Street Set to Open Flat Wednesday; Jobless Claims Fall More Than Expected | MT |
| Sales 2022 | 2.6M 208M | Sales 2023 | 1.97M 158M | Capitalization | 2.96M 237M |
|---|---|---|---|---|---|
| Net income 2022 | -5M -400M | Net income 2023 | -5M -400M | EV / Sales 2022 | 2.71 x |
| Net cash position 2022 | 4.33M 347M | Net cash position 2023 | 8.41M 673M | EV / Sales 2023 | -2.76 x |
| P/E ratio 2022 |
-1.02
x | P/E ratio 2023 |
-0.32
x | Employees | 78 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 77.99% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.94% | ||
| 1 week | -4.21% | ||
| Current month | -3.30% | ||
| 1 month | -38.25% | ||
| 3 months | -46.05% | ||
| 6 months | -54.65% | ||
| Current year | -74.18% |
1 week
1.00
1.13
1 month
0.943.37
Current year
0.943.37
1 year
0.949.38
3 years
0.941 140.00
5 years
0.9410 500.00
10 years
0.9446 700.00
| Managers | Title | Age | Since |
|---|---|---|---|
Feng Zhou
CEO | Chief Executive Officer | 32 | 03/07/17 |
Xiaodong Pan
DFI | Director of Finance/CFO | - | 30/01/22 |
Peter Chan
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Feng Zhou
CEO | Chief Executive Officer | 32 | 03/07/17 |
Jun Zheng
BRD | Director/Board Member | 47 | 30/12/18 |
Xiaodong Ji
BRD | Director/Board Member | 54 | 21/05/21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/05/24 | 1.025 | -3.30% | 81 450 |
| 30/04/24 | 1.06 | +2.91% | 186,719 |
| 29/04/24 | 1.03 | -1.90% | 345,643 |
| 26/04/24 | 1.05 | +1.94% | 203,439 |
| 25/04/24 | 1.03 | -3.74% | 142,837 |
Delayed Quote Nasdaq, May 01, 2024 at 05:04 pm
More quotes
China SXT Pharmaceuticals Inc is a China-based pharmaceutical company that focuses on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces (TCMP). The Company develops, manufactures and sells three types of TCMP products: advanced TCMP, fine TCMP and regular TCMP, and TCM Homologous Supplements (TCMHS) products. The Company sells its TCMP products under three brand names such as Suxuangtang, Hui Chun Tang and Tong Ren Tang. Most of its products are sold on a prescription basis across China.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -74.18% | 772K | |
| +32.66% | 704B | |
| +28.59% | 577B | |
| -3.77% | 348B | |
| +18.10% | 327B | |
| +5.46% | 288B | |
| +14.81% | 234B | |
| +4.93% | 198B | |
| -9.78% | 194B | |
| -4.05% | 147B |
- Stock Market
- Equities
- SXTC Stock
